Art***Pei

Strategy, Valuation, Business Development, Management Consulting

Healthcare system lead at Novartis

• Location: Shanghai, China
• Duration: 2023-04 to Present
• Description:

Chief of Staff and Director of Corp Strategy at Fosun Kite | 复星凯特

• Location:
• Duration: 2022-06 to 2023-04
• Description: Taking in charge of strategic works from corp level to commercial and portfolio. lead Yescarta and Tecartus new indication and new product planning Achived new round capital injections from shareholders Contribute to 52% QoQ sales growth and 163% YoY sales grwoth of Yescarta China sales Set 1/3/10 years company strategic planning and corp goals

Senior manager - BD and strategy at Overland Pharmaceuticals

• Location: 中国 上海市
• Duration: 2020-04 to 2022-06
• Description: Strategic partnering, joint venture, and license deal with overseas biotech companies. Independently close 2 deals with 11 products; ADCT: build joint venture with ADC Therapeutics with license of Phase 3 CD19 ADC and other 3 ADCs ALLO: build joint venture with Allogene with license of 5 globally first-in-class allo CAR-T in both solid tumor and hem-onc Company strategy and portfolio strategy: New product planning; corp 5-year planning etc.

Strategic Planning Manager at Roche

• Location: Shanghai
• Duration: 2020-01 to 2020-04
• Description: Took in charge of Roche oncology GI&GU franchise strategy and new product planning in China. Worked closely with Roche global Team to develop GI&GU oncology franchise strategy in China. Led a cross-functional team to build new product strategies including development strategy, portfolio prioritization, commercial assessment, business case, and revenue forecast, etc... Supported BU in marketed or pre-market product marketing strategies including pre-launch marketing, product pricing, market access, competitive intelligence, business case, and other market strategies.

Consulting Manager at Frost & Sullivan

• Location: Shanghai City, China
• Duration: 2017 to 2019-12
• Description: Led a 5-people team and conducted strategy, market intelligence analysis, valuation, and commercial DD of innovative drug sector in management consulting, IPOs, M&A and equity investment projects. Led 6 strategy consulting projects regarding BD, in-license deal & investment strategy, market access strategy, pricing strategy for biotech companies and multinational pharmaceutical companies. Involved in the over 20 HK/NASDAQ/SH IPO events of biotech companies like BeiGene, Innovent, WuxiApptec, HanSoh, and others. Involved in 1 M&A deal and 3 equity investment deals of biotech companies. Help such companies raising USD5.3 Billion in total. Supported and 10+ in-licenses deals in commercial assessment, revenue forecast and financial analysis. Sophisticated in valuation and revenue forecasting modeling, especially for the risk-adjusted DCF valuation model in the field of biotech and pharma.